KCPG
IONS icon

Kavar Capital Partners Group’s Ionis Pharmaceuticals IONS Stock Holding History

Kavar Capital Partners Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-9
Closed – – 279
2014
Q1 		$0 Sell
9
-2
-18% -$97 ﹤0.01% 553
2013
Q4 		$0 Buy
+11
New +$392 ﹤0.01% 510

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kavar Capital Partners Group's IONS Position: Q2 2014 in Review

Kavar Capital Partners Group sold out of Ionis Pharmaceuticals (IONS) in Q2 2014, closing a stake of 9 shares.

Kavar Capital Partners Group first reported a position in IONS in Q4 2013 and held it in 2 quarters. The position peaked at $0 in Q1 2014. 238 funds tracked by Wall St. Rank hold IONS as of Q2 2014.

  • Kavar Capital Partners Group reported no remaining Ionis Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Kavar Capital Partners Group sold 9 Ionis Pharmaceuticals shares in Q2 2014.
  • Kavar Capital Partners Group first reported a position in Ionis Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Kavar Capital Partners Group's Ionis Pharmaceuticals position peaked at $0 in Q1 2014.
  • 238 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2014.

Based on Kavar Capital Partners Group's 13F filing for Q2 2014, filed 25 Jan 2019.